Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Truth-telling and doctor-assisted death as perceived by Israeli physicians.

Velan B, Ziv A, Kaplan G, Rubin C, Connelly Y, Karni T, Tal O.

BMC Med Ethics. 2019 Feb 18;20(1):13. doi: 10.1186/s12910-019-0350-5.

2.

[Ethical standards of physicians in Israel 2018 report of the Chair of the Ethics Bureau of the Israel Medical Association (IMA)].

Karni T, Kaplan G, Ziv A, Connelly Y, Velan B, Tal O.

Harefuah. 2018 Dec;157(12):751-755. Hebrew. No abstract available.

PMID:
30582305
3.
4.

Using the social structure of markets as a framework for analyzing vaccination debates: The case of emergency polio vaccination.

Connelly Y, Ziv A, Goren U, Tal O, Kaplan G, Velan B.

Hum Vaccin Immunother. 2016 Jul 2;12(7):1930-5. doi: 10.1080/21645515.2016.1147637. Epub 2016 Apr 8.

5.

Vaccine hesitancy as self-determination: an Israeli perspective.

Velan B.

Isr J Health Policy Res. 2016 Apr 4;5:13. doi: 10.1186/s13584-016-0071-x. eCollection 2016.

6.

Analysis of public responses to preparedness policies: the cases of H1N1 influenza vaccination and gas mask distribution.

Velan B, Boyko V, Shenhar G, Lerner-Geva L, Kaplan G.

Isr J Health Policy Res. 2013 Mar 27;2(1):11. doi: 10.1186/2045-4015-2-11.

7.

Individualism, acceptance and differentiation as attitude traits in the public's response to vaccination.

Velan B, Boyko V, Lerner-Geva L, Ziv A, Yagar Y, Kaplan G.

Hum Vaccin Immunother. 2012 Sep;8(9):1272-82. doi: 10.4161/hv.21183. Epub 2012 Aug 16.

8.

Acceptance on the move: public reaction to shifting vaccination realities.

Velan B.

Hum Vaccin. 2011 Dec;7(12):1261-70. doi: 10.4161/hv.7.12.17980. Epub 2011 Dec 1. Review.

PMID:
22108039
9.

Major motives in non-acceptance of A/H1N1 flu vaccination: the weight of rational assessment.

Velan B, Kaplan G, Ziv A, Boyko V, Lerner-Geva L.

Vaccine. 2011 Feb 1;29(6):1173-9. doi: 10.1016/j.vaccine.2010.12.006. Epub 2010 Dec 16.

PMID:
21167862
10.

The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis.

Markel G, Bar-Haim E, Zahavy E, Cohen H, Cohen O, Shafferman A, Velan B.

PLoS One. 2010 Jun 18;5(6):e11176. doi: 10.1371/journal.pone.0011176.

11.

Next generation OP-bioscavengers: a circulatory long-lived 4-PEG hypolysine mutant of F338A-HuAChE with optimal pharmacokinetics and pseudo-catalytic characteristics.

Kronman C, Cohen O, Mazor O, Ordentlich A, Raveh L, Velan B, Shafferman A.

Chem Biol Interact. 2010 Sep 6;187(1-3):253-8. doi: 10.1016/j.cbi.2009.12.004. Epub 2009 Dec 11.

PMID:
20005217
12.

Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response.

Lustig S, Maik-Rachline G, Paran N, Melamed S, Israely T, Erez N, Orr N, Reuveny S, Ordentlich A, Laub O, Shafferman A, Velan B.

Vaccine. 2009 Mar 10;27(11):1691-9. doi: 10.1016/j.vaccine.2009.01.038. Epub 2009 Feb 3.

PMID:
19195492
13.

Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection.

Bar-Haim E, Gat O, Markel G, Cohen H, Shafferman A, Velan B.

PLoS Pathog. 2008 Nov;4(11):e1000211. doi: 10.1371/journal.ppat.1000211. Epub 2008 Nov 21.

14.

Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.

Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, Erez N, Levin R, Velan B, Löwer J, Shafferman A, Sutter G.

J Infect Dis. 2009 Jan 1;199(1):39-48. doi: 10.1086/595565.

PMID:
19012492
15.

Flexibility versus "rigidity" of the functional architecture of AChE active center.

Shafferman A, Barak D, Stein D, Kronman C, Velan B, Greig NH, Ordentlich A.

Chem Biol Interact. 2008 Sep 25;175(1-3):166-72. doi: 10.1016/j.cbi.2008.03.013. Epub 2008 Apr 8.

16.

Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.

Zauberman A, Cohen S, Levy Y, Halperin G, Lazar S, Velan B, Shafferman A, Flashner Y, Mamroud E.

Vaccine. 2008 Mar 20;26(13):1616-25. doi: 10.1016/j.vaccine.2008.01.033. Epub 2008 Feb 6.

PMID:
18304706
17.

Immunoscreening after hybrid selection and translation.

Velan B.

Curr Protoc Mol Biol. 2001 May;Chapter 6:Unit6.8. doi: 10.1002/0471142727.mb0608s13.

PMID:
18265263
18.

Disparity between Yersinia pestis and Yersinia enterocolitica O:8 in YopJ/YopP-dependent functions.

Zauberman A, Velan B, Mamroud E, Flashner Y, Shafferman A, Cohen S.

Adv Exp Med Biol. 2007;603:312-20.

PMID:
17966427
19.

Controlled concealment of exposed clearance and immunogenic domains by site-specific polyethylene glycol attachment to acetylcholinesterase hypolysine mutants.

Cohen O, Kronman C, Lazar A, Velan B, Shafferman A.

J Biol Chem. 2007 Dec 7;282(49):35491-501. Epub 2007 Oct 11.

20.

Discordance in the effects of Yersinia pestis on the dendritic cell functions manifested by induction of maturation and paralysis of migration.

Velan B, Bar-Haim E, Zauberman A, Mamroud E, Shafferman A, Cohen S.

Infect Immun. 2006 Nov;74(11):6365-76. Epub 2006 Aug 21.

21.

Interaction of Yersinia pestis with macrophages: limitations in YopJ-dependent apoptosis.

Zauberman A, Cohen S, Mamroud E, Flashner Y, Tidhar A, Ber R, Elhanany E, Shafferman A, Velan B.

Infect Immun. 2006 Jun;74(6):3239-50.

22.

Lessons from functional analysis of AChE covalent and noncovalent inhibitors for design of AD therapeutic agents.

Barak D, Ordentlich A, Kaplan D, Kronman C, Velan B, Shafferman A.

Chem Biol Interact. 2005 Dec 15;157-158:219-26. Epub 2005 Nov 11.

PMID:
16289124
23.

Host-regulated disposition of mammalian AChEs.

Kronman C, Cohen O, Velan B, Shafferman A.

Chem Biol Interact. 2005 Dec 15;157-158:51-5. Epub 2005 Nov 9.

PMID:
16289063
24.

The role of AChE active site gorge in determining stereoselectivity of charged and noncharged VX enantiomers.

Ordentlich A, Barak D, Sod-Moriah G, Kaplan D, Mizrahi D, Segall Y, Kronman C, Karton Y, Lazar A, Marcus D, Velan B, Shafferman A.

Chem Biol Interact. 2005 Dec 15;157-158:191-8. Epub 2005 Nov 10.

PMID:
16289014
25.

Functional requirements for the optimal catalytic configuration of the AChE active center.

Shafferman A, Barak D, Kaplan D, Ordentlich A, Kronman C, Velan B.

Chem Biol Interact. 2005 Dec 15;157-158:123-31. Epub 2005 Oct 27.

PMID:
16256968
26.

Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.

Mendelson I, Gat O, Aloni-Grinstein R, Altboum Z, Inbar I, Kronman C, Bar-Haim E, Cohen S, Velan B, Shafferman A.

Vaccine. 2005 Dec 1;23(48-49):5688-97. Epub 2005 Feb 5.

PMID:
16039760
27.

Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.

Aloni-Grinstein R, Gat O, Altboum Z, Velan B, Cohen S, Shafferman A.

Infect Immun. 2005 Jul;73(7):4043-53.

28.

Stereoselectivity toward VX is determined by interactions with residues of the acyl pocket as well as of the peripheral anionic site of AChE.

Ordentlich A, Barak D, Sod-Moriah G, Kaplan D, Mizrahi D, Segall Y, Kronman C, Karton Y, Lazar A, Marcus D, Velan B, Shafferman A.

Biochemistry. 2004 Sep 7;43(35):11255-65.

PMID:
15366935
29.

Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine.

Marcus H, Danieli R, Epstein E, Velan B, Shafferman A, Reuveny S.

Infect Immun. 2004 Jun;72(6):3471-7.

30.

Is aromaticity essential for trapping the catalytic histidine 447 in human acetylcholinesterase?

Kaplan D, Barak D, Ordentlich A, Kronman C, Velan B, Shafferman A.

Biochemistry. 2004 Mar 23;43(11):3129-36.

PMID:
15023064
31.
32.

Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates.

Flashner Y, Mamroud E, Tidhar A, Ber R, Aftalion M, Gur D, Lazar S, Zvi A, Bino T, Ariel N, Velan B, Shafferman A, Cohen S.

Infect Immun. 2004 Feb;72(2):908-15.

33.
34.

Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens.

Ariel N, Zvi A, Makarova KS, Chitlaru T, Elhanany E, Velan B, Cohen S, Friedlander AM, Shafferman A.

Infect Immun. 2003 Aug;71(8):4563-79.

35.

Evaluation of protective immunity induced by Yersinia enterocolitica type-III secretion system mutants.

Mamroud E, Flashner Y, Tidhar A, Ber R, Gur D, Aftalion M, Lazar S, Velan B, Shafferman A, Cohen S.

Adv Exp Med Biol. 2003;529:425-30. No abstract available.

PMID:
12756803
36.

Vaccination with plasmid DNA expressing the Yersinia pestis capsular protein F1 protects mice against plague.

Grosfeld H, Bino T, Flashner Y, Ber R, Mamroud E, Lustig S, Velan B, Shafferman A, Cohen S.

Adv Exp Med Biol. 2003;529:423-4. No abstract available.

PMID:
12756802
37.

Identification of genes involved in Yersinia pestis virulence by signature-tagged mutagenesis.

Flashner Y, Mamroud E, Tidhar A, Ber R, Aftalion M, Gur D, Zvi A, Ariel N, Velan B, Shafferman A, Cohen S.

Adv Exp Med Biol. 2003;529:31-3. No abstract available.

PMID:
12756723
38.

Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines.

Gat O, Inbar I, Aloni-Grinstein R, Zahavy E, Kronman C, Mendelson I, Cohen S, Velan B, Shafferman A.

Infect Immun. 2003 Feb;71(2):801-13.

39.

Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen.

Grosfeld H, Cohen S, Bino T, Flashner Y, Ber R, Mamroud E, Kronman C, Shafferman A, Velan B.

Infect Immun. 2003 Jan;71(1):374-83.

40.

Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening.

Ariel N, Zvi A, Grosfeld H, Gat O, Inbar Y, Velan B, Cohen S, Shafferman A.

Infect Immun. 2002 Dec;70(12):6817-27.

41.

The aromatic "trapping" of the catalytic histidine is essential for efficient catalysis in acetylcholinesterase.

Barak D, Kaplan D, Ordentlich A, Ariel N, Velan B, Shafferman A.

Biochemistry. 2002 Jul 2;41(26):8245-52.

PMID:
12081473
42.
43.

Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity.

Cohen O, Kronman C, Chitlaru T, Ordentlich A, Velan B, Shafferman A.

Biochem J. 2001 Aug 1;357(Pt 3):795-802.

44.

Resolving pathways of interaction of covalent inhibitors with the active site of acetylcholinesterases: MALDI-TOF/MS analysis of various nerve agent phosphyl adducts.

Elhanany E, Ordentlich A, Dgany O, Kaplan D, Segall Y, Barak R, Velan B, Shafferman A.

Chem Res Toxicol. 2001 Jul;14(7):912-8.

PMID:
11453739
45.
46.

Search for correlates of protective immunity conferred by anthrax vaccine.

Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, Gozes Y, Kobiler D, Shafferman A, Velan B.

Infect Immun. 2001 May;69(5):2888-93.

47.

Effect of human acetylcholinesterase subunit assembly on its circulatory residence.

Chitlaru T, Kronman C, Velan B, Shafferman A.

Biochem J. 2001 Mar 15;354(Pt 3):613-25.

48.

Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II.

Kryger G, Harel M, Giles K, Toker L, Velan B, Lazar A, Kronman C, Barak D, Ariel N, Shafferman A, Silman I, Sussman JL.

Acta Crystallogr D Biol Crystallogr. 2000 Nov;56(Pt 11):1385-94.

PMID:
11053835
49.

Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.

Cohen S, Mendelson I, Altboum Z, Kobiler D, Elhanany E, Bino T, Leitner M, Inbar I, Rosenberg H, Gozes Y, Barak R, Fisher M, Kronman C, Velan B, Shafferman A.

Infect Immun. 2000 Aug;68(8):4549-58.

Supplemental Content

Support Center